Single Ascending Dose of ASP3772 Study in Japanese Healthy Male and Female Adults, and Single Ascending Dose Study of ASP3772 in Comparison With PPSV23 in Japanese Elderly Male and Female Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

126 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-02-19

Study Completion Date

2020-11-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety and tolerability of 3 different dose levels of ASP3772 administered subcutaneously or intramuscularly to Japanese healthy adults 20 to 49 years of age.

This study will also evaluate the safety and tolerability of 3 different dose levels of ASP3772 administered subcutaneously or intramuscularly, in comparison to the active comparator 23-valent pneumococcal polysaccharide vaccine (PPSV23) in Japanese elderly subjects 65 to 85 years of age.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of AZD1222 for the Prevention of COVID-19 in Japan

NCT04568031

COVID-19

COMPLETED PHASE1/PHASE2

Study of AZD3152 Intramuscular Injection or Intravenous Infusion in Healthy Japanese Adult Participants

NCT05932641

COVID-19, SARS-CoV-2

COMPLETED PHASE1

Study to Assess Safety, Tolerability and Pharmacokinetics After Single Dose of AZD2516 to Japanese Healthy Subjects

NCT00972049

Healthy

COMPLETED PHASE1

A Study to Evaluate the Immune Response to the ASP7373 and Its Safety in Healthy Adult Volunteers

NCT01450579

Healthy

COMPLETED PHASE2

Assess Safety, Tolerability and Pharmacokinetic (PK) of AZD1704 in Healthy Japanese Male and Non-Fertile Female Volunteers

NCT00736788

Healthy Volunteers

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ASP3772 (subcutaneous) in Adults

Participants will receive a single dose of ASP3772 administered as an subcutaneous injection on Day 1 at one of three dose levels.

Group Type EXPERIMENTAL

ASP3772 (subcutaneous)

Intervention Type BIOLOGICAL

Subcutaneous injection

ASP3772 ((intramuscular) in Adults

Participants will receive a single dose of ASP3772 administered as an intramuscular injection on Day 1 at one of three dose levels.

Group Type EXPERIMENTAL

ASP3772 (intramuscular)

Intervention Type BIOLOGICAL

Intramuscular injection

ASP3772 (subcutaneous) in Elderly

Participants will receive a single dose of ASP3772 administered as an subcutaneous injection on Day 1 at one of three dose levels.

Group Type EXPERIMENTAL

ASP3772 (subcutaneous)

Intervention Type BIOLOGICAL

Subcutaneous injection

ASP3772 (intramuscular) in Elderly

Participants will receive a single dose of ASP3772 administered as an intramuscular injection on Day 1 at one of three dose levels

Group Type EXPERIMENTAL

ASP3772 (intramuscular)

Intervention Type BIOLOGICAL

Intramuscular injection

PPSV23 (subcutaneous) in Elderly

Participants will receive a single subcutaneous injection of the standard dose of PPSV23 on Day 1.

Group Type ACTIVE_COMPARATOR

PPSV23 (subcutaneous)

Intervention Type BIOLOGICAL

Subcutaneous injection

PPSV23 (intramuscular) in Elderly

Participants will receive a single intramuscular injection of the standard dose of PPSV23 on Day 1.

Group Type ACTIVE_COMPARATOR

PPSV23 (intramuscular)

Intervention Type BIOLOGICAL

Intramuscular injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ASP3772 (subcutaneous)

Subcutaneous injection

Intervention Type BIOLOGICAL

ASP3772 (intramuscular)

Intramuscular injection

Intervention Type BIOLOGICAL

PPSV23 (subcutaneous)

Subcutaneous injection

Intervention Type BIOLOGICAL

PPSV23 (intramuscular)

Intramuscular injection

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Pneumovax NP Pneumovax NP

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Group 1: Subject is a healthy male or female between 20 and 49 years of age inclusive, at informed consent.
* Group 2: Subject is a male or female between 65 and 85 years of age inclusive, at informed consent who is healthy or has chronic controlled, stable disease with no change in disease severity, medical therapy and no hospitalization history in last 12 weeks from informed consent as determined by medical history, physical examination, and laboratory data.
* Female subject of non-childbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.
* Subject agrees not to participate in another interventional study while participating in the present study.
* Subject has a body mass index (BMI) range of 17.6 to 26.4 kg/m\^2 inclusive in Group 1 and 15.4 to 28.6 kg/m\^2 inclusive in Group 2, and body weight at least 50 kg for male and 40 kg for female at screening.

Exclusion Criteria

* Subject has had previous vaccination with any licensed or investigational pneumococcal vaccine at any time.
* Subject has a history of microbiologically-proven invasive disease caused by Streptococcus pneumoniae.
* Subject has an immune disorder(s) (including autoimmune disease), clinical conditions requiring immunosuppressive drugs and/or a close relative who has congenital immunodeficiency.
* Group 1: Subject has any illness that requires medication or treatment.
* Group 2: Subject has any evidence of unstable or active clinically significant cardiovascular, gastrointestinal, endocrine, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal and/or other major disease, e.g., uncontrolled hypertension, uncontrolled diabetes, heart failure, uncontrolled chronic obstructive pulmonary disease, end-stage renal disease, malignancy which is active and requires treatment.
* Subject has any clinically significant history of allergic conditions including drug allergies, asthma or anaphylactic reactions, but excluding untreated asymptomatic seasonal allergies just before study vaccine administration.
* Subject has a positive serology test for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), hepatitis A virus antibodies (immunoglobulin M), hepatitis C virus antibodies (anti-HCV) or antigens/antibodies to human immunodeficiency virus (HIV) type 1 and/or type 2 at screening.
* Subject has/had febrile illness or symptomatic of viral, bacterial (including upper respiratory infection) or fungal (excluding skin infection) infection within 7 days prior to day 1.

Minimum Eligible Age

20 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes